Oct 02, 2026 4:30 pm EDT Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
Oct 01, 2026 4:05 pm EDT Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
Sep 29, 2026 4:05 pm EDT Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Sep 24, 2026 4:05 pm EDT Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Sep 23, 2026 4:05 pm EDT Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
Sep 21, 2026 4:05 pm EDT Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Sep 09, 2026 4:05 pm EDT Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Aug 26, 2026 8:00 am EDT Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Aug 13, 2026 4:05 pm EDT Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Aug 11, 2026 4:05 pm EDT Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
